Senseonics has agreed to integrate its real-time glucose data with the Companion Medical InPen smart system for insulin delivery.
Senseonics Holdings (NYSEAMERICAN:SENS) entered into an agreement with Companion Medical to integrate the Eversense CGM System real-time glucose data with the Companion Medical InPen smart system for insulin delivery.
As quoted in the press release:
For people living with insulin-dependent diabetes, this news means that real-time glucose data will continuously be incorporated into their InPen insulin system allowing for more relevant insulin dosing information which will inform improved diabetes management decisions.
“There is a strong desire from people living with diabetes to have a complete picture of their real-time glucose values, rate of change and insulin information in one place so they can make better diabetes management decisions,” said Tim Goodnow, PhD, President and CEO of Senseonics. “By partnering with Companion Medical, multiple daily injection patients using the InPen System will be able to take full advantage of the convenience of insightful and comprehensive insulin data integrated with their Eversense CGM data, giving them a more complete picture and meaningful information at their fingertips.”